Zhitong Financial App News, China Environmental Protection Technology (00646) issued an announcement that on November 28, 2021, the buyer (Winsum Investment Limited, a wholly-owned subsidiary of the company) and the seller (Zhong Shen Cambodia and Yang Caiyun) signed a sale and purchase agreement. The seller conditionally agreed to sell 51% of the target company (Cambodia-China Biological Research Holdings Co., Ltd.) for a transaction consideration of HK $100000.

It is reported that the main business of the target company is biological cell storage services, biological cold chain logistics, biological consulting services, sales and communication and promotion of biotechnology, as well as the sale of medical devices, biological data and health products. The target group is a partner of NSCTRC and is responsible for the marketing and operation management of NSCTRC storage cell samples. On the date of this announcement, the Target Group indicates to the directors that it is the only partner in NSCTRC in this field. In addition, the target group develops its own cold chain logistics, including, but not limited to, refrigerated vehicles specially designed for stem cell preparation and transport, as well as a mobile application to track the sending and storage status of biological cells. Moreover, the target group has signed a cooperation agreement with GBHRC to operate and promote the products and technology solutions developed by GBHRC. The target group is also working with GBHRC to develop training programs and storage services related to urine stem cells. In addition, the target group signed an intention agreement with the government of Wujiang District, Shaoguan City, Guangdong Province to jointly invest in the construction of NSCTRC primate Reserve Experimental Center in Wujiang District, Shaoguan City, Guangdong Province.

The acquisition will expand the group's ability to serve the cell biology industry, the announcement said. Given that there are only a small number of participants in the biological cell services industry, which are not yet of a large scale, the Board believes that the acquisition will make the Group one of the leading participants in the industry sector and give the Group a significant share of the market. The Board believes that this is a good business prospect and development opportunity for the Group, which may also increase the Group's revenue base and strengthen the Group's position in the biomedical field.